Palatin Technologies, Inc. To Report Fiscal Year 2010 First Quarter Results; Teleconference and Webcast to be held on November 16, 2009

Friday, November 13, 2009 General News J E 4

CRANBURY, N.J., Nov. 12 Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its first quarter, fiscal year 2010 financial results on Monday, November 16, 2009 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 16, 2009, which will include discussion of the results of operations in greater detail and an update on corporate developments.

Schedule for the Financial Results Press Release, Conference Call / Webcast

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at .

-- Q1 & Fiscal Year 2010 Financial Results Press Release 11/16/2009 at 7:30 a.m. ET -- Q1 & Fiscal Year 2010 Conference Call-Live 11/16/2009 at 11:00 a.m. ET Domestic Dial-In Number 1-888-801-6504 International Dial-In Number 1-913-312-4376 Passcode 8561334 -- Q1 & Fiscal Year 2010 Conference Call-Replay 11/16-11/23/2009 Domestic Dial-In Number 1-888-203-1112 International Dial-In Number 1-719-457-0820 Passcode 8561334 -- Webcast Live and Replay Access The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at

SOURCE Palatin Technologies, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Frost & Sullivan Recognizes Fovia for its HDVR(R) ...
Mersana Therapeutics Publishes Review Article Deta...